These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23445611)

  • 21. Galectin-1 Modulates the Survival and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity in Human Hepatocellular Carcinoma Cells.
    Li J; Sun RR; Yu ZJ; Liang H; Shen S; Kan Q
    Cancer Biother Radiopharm; 2015 Oct; 30(8):336-41. PubMed ID: 26348206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thiourea compound AW00178 sensitizes human H1299 lung carcinoma cells to TRAIL-mediated apoptosis.
    Ryu BJ; Hwang MK; Park M; Lee K; Kim SH
    Bioorg Med Chem Lett; 2012 Jun; 22(12):3862-5. PubMed ID: 22622069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Piperine enhances the efficacy of TRAIL-based therapy for triple-negative breast cancer cells.
    Abdelhamed S; Yokoyama S; Refaat A; Ogura K; Yagita H; Awale S; Saiki I
    Anticancer Res; 2014 Apr; 34(4):1893-9. PubMed ID: 24692724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A moderate static magnetic field enhances TRAIL-induced apoptosis by the inhibition of Cdc2 and subsequent downregulation of survivin in human breast carcinoma cells.
    Lin T; Wan L; Qi X; Shi W; Lin J
    Bioelectromagnetics; 2014 Jul; 35(5):337-46. PubMed ID: 24619849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitization of rhTRAIL-resistant Triple-negative Breast Carcinoma Through Silibinin Co-Treatment.
    Manouchehri JM; Kalafatis M
    Anticancer Res; 2017 Dec; 37(12):6593-6599. PubMed ID: 29187434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting PP2A inhibits the growth of triple-negative breast cancer cells.
    Uddin MH; Pimentel JM; Chatterjee M; Allen JE; Zhuang Z; Wu GS
    Cell Cycle; 2020 Mar; 19(5):592-600. PubMed ID: 32011210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
    Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
    Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.
    Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y
    Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
    Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
    Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation.
    Cheng S; Huang Y; Lou C; He Y; Zhang Y; Zhang Q
    Cancer Biol Ther; 2019; 20(3):328-337. PubMed ID: 30336071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
    Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
    Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
    Strekalova E; Malin D; Rajanala H; Cryns VL
    Breast Cancer Res Treat; 2017 Jun; 163(3):435-447. PubMed ID: 28324269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids.
    Chandrasekaran S; Marshall JR; Messing JA; Hsu JW; King MR
    PLoS One; 2014; 9(10):e111487. PubMed ID: 25343626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Xu K; Yagüe E
    Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer.
    Hallett RM; Kondratyev MK; Giacomelli AO; Nixon AM; Girgis-Gabardo A; Ilieva D; Hassell JA
    PLoS One; 2012; 7(3):e33976. PubMed ID: 22470504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells.
    Wang C; Zheng X; Shen C; Shi Y
    J Exp Clin Cancer Res; 2012 Jun; 31(1):58. PubMed ID: 22713668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
    Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
    Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
    Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.
    Lin CC; Lo MC; Moody R; Jiang H; Harouaka R; Stevers N; Tinsley S; Gasparyan M; Wicha M; Sun D
    Cancer Lett; 2018 Dec; 438():165-173. PubMed ID: 30227220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway.
    Xia Y; He Z; Liu B; Wang P; Chen Y
    Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.